In 2019, Moderna reported revenues of sixty million dollars. By 2022 it was number 195 on the Fortune 500 with over $18 billion in revenue. This meteoric rise was due to Moderna's development of one of the major COVID-19 vaccines. Now, thankfully, the height of the pandemic has passed and the need for these vaccines is far less urgent. There is something to be said about your marquee product being less useful because people are healthier, but where does Moderna go from here? And how will its CEO Stéphane Bancel help it get there?
In this episode of Leadership Next, Bancel talks with hosts Alan Murray and Michal Lev-Ram about the other uses for Moderna's proprietary mRNA platform - including potential vaccines for cancer and H.I.V. Bancel also discusses Moderna's controversial plan to start charging as much as $130 a dose for the COVID-19 vaccine once the U.S. ends the pandemic public health emergency on May 11th.
Explore more of Fortune! Use the promo code LN25 to get 25% off an annual subscription at fortune.com/subscribe.
Leadership Next is powered by Deloitte.